Gujarat Themis Biosyn Ltd vs Hindustan Bio Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Gujarat Themis Biosyn Ltd is ₹ 382.7 as of 05 May 15:30 . The P/E Ratio of Gujarat Themis Biosyn Ltd changed from 9.8 on March 2021 to 62.8 on March 2025 . This represents a CAGR of 44.99% over 5 yearsThe P/E Ratio of Hindustan Bio Sciences Ltd changed from 120.8 on March 2024 to 69.8 on March 2025 . This represents a CAGR of -23.99% over 2 years The Market Cap of Gujarat Themis Biosyn Ltd changed from ₹ 295.88 crore on March 2021 to ₹ 3067 crore on March 2025 . This represents a CAGR of 59.64% over 5 yearsThe Market Cap of Hindustan Bio Sciences Ltd changed from ₹ 15.38 crore on March 2021 to ₹ 7.16 crore on March 2025 . This represents a CAGR of -14.18% over 5 years The revenue of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 43.78 crore as compare to the Sep '25 revenue of ₹ 43.17 crore. This represent the growth of 1.41% The revenue of Hindustan Bio Sciences Ltd for the Dec '25 is ₹ 0.4 crore as compare to the Sep '25 revenue of ₹ 0.01 crore. This represent the growth of 3900% The ebitda of Gujarat Themis Biosyn Ltd for the Dec '25 is ₹ 21.72 crore as compare to the Sep '25 ebitda of ₹ 21.76 crore. This represent the decline of -0.18% The ebitda of Hindustan Bio Sciences Ltd for the Dec '25 is ₹ 0.09 crore as compare to the Sep '25 ebitda of ₹ -0.05 crore. This represent the decline of -280% The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 13.24 crore to ₹ 12.46 crore over 7 quarters. This represents a CAGR of -3.41% The net profit of Hindustan Bio Sciences Ltd changed from ₹ 0.08 crore to ₹ 0.08 crore over 7 quarters. This represents a CAGR of 0.00% The Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 14.97 % on March 2025 . This represents a CAGR of -20.04% over 4 yearsThe Dividend Payout of Hindustan Bio Sciences Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

About Hindustan Bio Sciences Ltd

Hindustan Bio Science Ltd (Formerly known Hindustan Softel Ltd) was incorporated as Public Limited Company on December 16, 1991.
The Company engaged in the manufacturing and sale of pharmaceutical products is an integrated firm with diversified operations in pharmaceutical and biotechnology sectors.
The Company initially commenced operations in 1992 by sourcing bulk drugs (APIs) and drug intermediates for the Industry with a wellspring of global suppliers and associates. Previously, it was engaged in cement manufacturing and due to sluggish in the industry the company diversified its business into Bio Technology & Pharmaceuticals activities and the name of the Company was changed from Garuda Cements to Hindustan Bio-Sciences Ltd. In 2001, it diversified into software field and subsequently changed its name to Hindustan Softel Limited which presently got changed into Hindustan Bio Sciences Ltd.

FAQs for the comparison of Gujarat Themis Biosyn Ltd and Hindustan Bio Sciences Ltd

Which company has a larger market capitalization, Gujarat Themis Biosyn Ltd or Hindustan Bio Sciences Ltd?

Market cap of Gujarat Themis Biosyn Ltd is 4,170 Cr while Market cap of Hindustan Bio Sciences Ltd is 9 Cr

What are the key factors driving the stock performance of Gujarat Themis Biosyn Ltd and Hindustan Bio Sciences Ltd?

The stock performance of Gujarat Themis Biosyn Ltd and Hindustan Bio Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Themis Biosyn Ltd and Hindustan Bio Sciences Ltd?

As of May 5, 2026, the Gujarat Themis Biosyn Ltd stock price is INR ₹382.7. On the other hand, Hindustan Bio Sciences Ltd stock price is INR ₹8.96.

How do dividend payouts of Gujarat Themis Biosyn Ltd and Hindustan Bio Sciences Ltd compare?

To compare the dividend payouts of Gujarat Themis Biosyn Ltd and Hindustan Bio Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.